Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Can Zytiga Prevail In Pre-Chemo Prostate Cancer Without Proof Of Survival Benefit?

17 Dec 2012

• By Mary Jo Laffler

Related Content

Zytiga Pre-chemo Data Impress At ASCO, But Early Trial Termination Could Be An Issue

03 Jun 2012

Data At ASCO From J&J Zytiga Trial’s Early End = Intel For Medivation’s MDV3100 Program

18 Jun 2012

As <em>Provenge</em> Sales Dip, Dendreon Hopes Restructuring Is The Answer

31 Jul 2012

Medivation/Astellas’ <em>Xtandi</em> A Tough Rival For J&J’s <em>Zytiga</em>

10 Sep 2012

J&J’s <em>Zytiga</em> –The Anatomy Of A Cancer Launch

30 Nov 2011

Related Companies

Johnson & Johnson

Medivation, Inc.

Astellas Pharma, Inc.

Additional Topics

Clinical Trials Advertising, Marketing & Sales Launches BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.